Porton Fine Chemicals Ltd (300363) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.023x

Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.55 Million ≈ $18.52 Million USD) by net assets (CN¥5.49 Billion ≈ $803.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Porton Fine Chemicals Ltd to measure how much of total assets are equity-financed.

Porton Fine Chemicals Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Porton Fine Chemicals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Porton Fine Chemicals Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Porton Fine Chemicals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Porton Fine Chemicals Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
ITMAX System Berhad
KLSE:5309
-0.009x
Anhui Shanying Paper Industry Co Ltd
SHG:600567
0.050x
Everi Holdings Inc
NYSE:EVRI
1.295x
Playtika Holding Corp
NASDAQ:PLTK
-1.563x
Hunan Corun New Energy Co Ltd
SHG:600478
0.004x
VIA Technologies Inc
TW:2388
0.109x
Jinhui Liquor Co Ltd
SHG:603919
-0.011x
CVR Partners LP
NYSE:UAN
0.243x

Annual Cash Flow Conversion Efficiency for Porton Fine Chemicals Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Porton Fine Chemicals Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Porton Fine Chemicals Ltd (300363) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.41 Billion
≈ $791.83 Million
CN¥405.53 Million
≈ $59.34 Million
0.075x -27.33%
2023-12-31 CN¥6.10 Billion
≈ $892.61 Million
CN¥629.06 Million
≈ $92.05 Million
0.103x -73.97%
2022-12-31 CN¥6.47 Billion
≈ $947.10 Million
CN¥2.56 Billion
≈ $375.26 Million
0.396x +245.42%
2021-12-31 CN¥4.19 Billion
≈ $612.56 Million
CN¥480.17 Million
≈ $70.26 Million
0.115x -22.83%
2020-12-31 CN¥3.39 Billion
≈ $496.54 Million
CN¥504.37 Million
≈ $73.81 Million
0.149x +29.63%
2019-12-31 CN¥3.06 Billion
≈ $448.41 Million
CN¥351.37 Million
≈ $51.42 Million
0.115x +70.75%
2018-12-31 CN¥2.88 Billion
≈ $421.91 Million
CN¥193.62 Million
≈ $28.33 Million
0.067x -66.38%
2017-12-31 CN¥1.45 Billion
≈ $212.07 Million
CN¥289.46 Million
≈ $42.36 Million
0.200x -4.09%
2016-12-31 CN¥1.37 Billion
≈ $200.49 Million
CN¥285.33 Million
≈ $41.75 Million
0.208x +118.72%
2015-12-31 CN¥1.18 Billion
≈ $172.60 Million
CN¥112.31 Million
≈ $16.43 Million
0.095x -31.71%
2014-12-31 CN¥874.42 Million
≈ $127.96 Million
CN¥121.92 Million
≈ $17.84 Million
0.139x -47.62%
2013-12-31 CN¥428.43 Million
≈ $62.69 Million
CN¥114.05 Million
≈ $16.69 Million
0.266x -23.60%
2012-12-31 CN¥327.76 Million
≈ $47.96 Million
CN¥114.21 Million
≈ $16.71 Million
0.348x +31.02%
2011-12-31 CN¥246.01 Million
≈ $36.00 Million
CN¥65.43 Million
≈ $9.57 Million
0.266x +21.40%
2010-12-31 CN¥163.21 Million
≈ $23.88 Million
CN¥35.75 Million
≈ $5.23 Million
0.219x -44.12%
2009-12-31 CN¥81.60 Million
≈ $11.94 Million
CN¥31.99 Million
≈ $4.68 Million
0.392x --

About Porton Fine Chemicals Ltd

SHE:300363 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.24 Billion
CN¥8.45 Billion CNY
Market Cap Rank
#7884 Global
#1750 in China
Share Price
CN¥15.54
Change (1 day)
+3.81%
52-Week Range
CN¥13.32 - CN¥29.41
All Time High
CN¥97.10
About

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more